Kuo-Shyan Lin

Alpha-9 Theranostics, Inc. operates as a clinical stage radiopharmaceutical company. It engages in developing breakthrough targeting agents for cancer imaging by positron emission tomography (PET) and therapy using targeted radioisotopes. The company was founded by Fran?ois B?nard, David Perrin, Kuo-Shyan Lin, and Ian McBeath and is headquartered in Vancouver, Canada.

Alpha-9 Theranostics, Inc. operates as a clinical stage radiopharmaceutical company. It engages in developing breakthrough targeting agents for cancer imaging by positron emission tomography (PET) and therapy using targeted radioisotopes. The company was founded by Fran?ois B?nard, David Perrin, Kuo-Shyan Lin, and Ian McBeath and is headquartered in Vancouver, Canada.

Alpha-9 Theranostics, Inc. operates as a clinical stage radiopharmaceutical company. It engages in developing breakthrough targeting agents for cancer imaging by positron emission tomography (PET) and therapy using targeted radioisotopes. The company was founded by Fran?ois B?nard, David Perrin, Kuo-Shyan Lin, and Ian McBeath and is headquartered in Vancouver, Canada.

Alpha-9 Theranostics, Inc. operates as a clinical stage radiopharmaceutical company. It engages in developing breakthrough targeting agents for cancer imaging by positron emission tomography (PET) and therapy using targeted radioisotopes. The company was founded by Fran?ois B?nard, David Perrin, Kuo-Shyan Lin, and Ian McBeath and is headquartered in Vancouver, Canada.

Alpha-9 Theranostics, Inc. operates as a clinical stage radiopharmaceutical company. It engages in developing breakthrough targeting agents for cancer imaging by positron emission tomography (PET) and therapy using targeted radioisotopes. The company was founded by Fran?ois B?nard, David Perrin, Kuo-Shyan Lin, and Ian McBeath and is headquartered in Vancouver, Canada.